Numerous diverse biological pathways are dysregulated in the epileptic focus. Which of these pathways are most critical in producing the biological abnormalities that lead to epilepsy? Answering this question is key to identifying the primary causes of epilepsy and for discovering new therapeutic strategies with greater efficacy than currently available antiepileptics (AEDs). We have performed the largest genome-wide transcriptomic analysis to date comparing epileptic with normal human hippocampi. We have identified 118 differentially expressed and, for the first time, differentially connected pathways in the epileptic focus. Using network mapping techniques, we have shown that these dysregulated pathways, though seemingly disparate, form a coherent interconnected central network. Using closeness centrality analysis, we have identified that the most influential hub pathways in this network are signalling through G protein-coupled receptors, in particular opioid receptors, and their downstream effectors PKA/CREB and DAG/IP 3 . Next, we have objectively demonstrated that genetic association of gene sets in independent genome-wide association studies (GWASs) can be used to identify causally relevant gene sets: we show that proven causal epilepsy genes, which cause familial Mendelian epilepsy syndromes, are associated in published sporadic epilepsy GWAS results. Using the same technique, we have shown that central pathways identified (opioid receptor and PKA/CREB and DAG/IP 3 signalling pathways) are genetically associated with focal epilepsy and, hence, likely causal. Published functional studies in animal models provide evidence of a role for these pathways in epilepsy. Our work shows that these pathways play a central role in human focal epilepsy and that they are important currently unexploited antiepileptic drug targets. † As senior authors, A.G.M. and M.P. contributed equally for this study.
Introduction
Epilepsies are amongst the most common neurological disorders, affecting up to 1% of the population (1) . Focal epilepsy, in which seizures originate in networks limited to one cerebral hemisphere (2) , is the most common form of epilepsy. Epilepsy is a complex genetic disease: hundreds, perhaps thousands, of genes influence susceptibility to epilepsy (3) . The identity of these genes remains unknown. Given the multiplicity of genes involved, a biological pathway-based analytical approach is more likely to be successful in identifying the most important processes underlying epilepsy.
In human focal epilepsy, pathway-level analyses have been performed on both genetic and transcriptomic data. Gene ontology (GO) gene-set enrichment (a variant of pathway analysis) of a meta-analysis of focal epilepsy genome-wide association studies (4) produced no significant results, at least in part owing to the multiple testing burden imposed owing to non-selective testing of all gene sets in the GO database. On the other hand, numerous diverse biological pathways have been shown to be dysregulated in transcriptomic analyses of human epileptic foci (5) . Hence, transcriptomic data represent the more promising resource for exploring the dysregulated pathways underlying epilepsy. However, not all of the identified differentially expressed pathways will be equally important in causing epilepsy: some will be critical, some peripheral and others simply reactive. Which of these pathways are most critical in producing the biological abnormalities that lead to epilepsy? Answering this question is key to identifying the primary causes of epilepsy and for discovering new therapeutic strategies with greater efficacy than currently available antiepileptics, which fail to control seizures in 30% of patients (6) .
An effective strategy for identifying pathways of greatest influence is to exploit network biology. Biological pathways function within large networks (7) . Central nodes in biological pathways are critical (8) . Hence, the most central pathways in the disease network are likely to be the most important pathways underlying the disease. Likely causal pathways from amongst these can then be identified through selective genome-wide association study enrichment analysis.
A number of large-scale gene expression profiling studies comparing epileptic with normal human brain tissue have been published (5) . However, these studies suffer from a number of weaknesses (5) . For example, the studies have been limited to an analysis of differential expression, and differential connectivity (or differential co-expression) has not been analysed.
In the current analysis, we have performed a large and robust microarray analysis of human epileptic foci. We have identified differentially expressed and differentially connected pathways, the network of dysregulated pathways and the most central pathways within this network. We have integrated our transcriptomic results with independent genome-wide association study data to show that causal relevance of our results and to identify central and likely causal pathways underlying epilepsy.
Results

Patient data and quality control
We performed genome-wide gene expression microarray analysis of hippocampal tissue from patients with pharmacoresistant mesial temporal lobe epilepsy who had undergone therapeutic temporal lobectomy and from normal post-mortem controls. One array was excluded as it failed on five of the quality metrics generated by the Feature Extraction Software. Of the remaining arrays, none were deemed to be outliers based on inter-array correlation, and all were included in subsequent analyses. Important characteristic of the included epilepsy patients (24 individuals, mean age 36.3 years, 50% males) and normal tissue donors (23 individuals, mean age 54 years, 74% males) are listed in Table 1 . We confirmed that, after ComBat and Independent Surrogate Variable Analysis (ISVA) treatment, confounders had been adjusted for appropriately: no probes were associated [at false discovery rate (FDR) < 0.10] with RIN, age, batch or sex in the adjusted data. 
Differential expressed genes
A total of 1009 genes were found to be significantly (FDR < 0.05) differentially expressed by 1.5-fold or more.
External validation of differentially expressed genes (DEGs)
There was a highly statistically significant overlap between the DEG list from our study and from three previously published microarray studies on pharmacoresistant epileptic hippocampal tissue (Table 2) . Furthermore, the rank-order similarity of the DEGs from our study and the previously published studies was statistically significant (Table 2 ). For comparison, we demonstrated that our results show neither a significant overlap nor a significant rank-order similarity with a previously published microarray study on hippocampal tissue from Alzheimer's disease sufferers.
Differential connectivity
For performing differential connectivity analysis, we used the algorithm Differential Correlation in Expression for meta-module Recovery (DICER) (9) . DICER produced 36 differentially connected clusters, ranging in size from 15 genes to 102 genes. The contents of each cluster are tabulated Supplementary Table S1 . The plot in Figure 1 illustrates, as an example, the clearly contrasting connectivity between normal and disease tissue for one of the clusters.
In total, 890 of the 10 000 genes (9%) included in the DICER analysis were found to be differentially connected. While 211 of these genes were also found in our list of differentially expressed genes, the majority (76%) were differentially connected without being significantly differentially expressed.
Causal relevance of transcriptomic changes
Validation of using genetic association to demonstrate causal relevance of genes We showed that a set of 111 proven causal epilepsy genes, which cause familial Mendelian disorders in which epilepsy/seizures are a primary feature, are highly enriched in a published (10) focal epilepsy genome-wide association study (GWAS) (P < 3.3 × 10 −7 for full and linkage disequilibrium (LD)-pruned GWAS results, permutation-based FDR < 1 × 10 −6 ).
Causal relevance of DEGs
Our DEG set was significantly enriched in the focal epilepsy GWAS (P < 1 × 10 −22 , permutation-based FDR < 1 × 10 −6 ). DEG sets from a number of previously published microarray studies on brain tissue from epilepsy surgery were significantly enriched in the focal epilepsy GWAS study, but the most significant enrichment by far was for our microarray study (Table 3) . Using the second best SNP did not lead to a significant change in the association of the DEG set (P < 7.1 × 10 −22 , permutationbased FDR < 1 × 10 −6 ), indicating that the DEG-set association is not inflated owing to random SNPs being highly associated by chance in the GWAS. Also, the DEG set remained highly significant in the LD-pruned GWAS results (P < 3.5 × 10 −20 , permutation-based FDR < 1 × 10 −6 ), showing that LD between genes in the DEG set is unlikely to be inflating the significance of its genetic association. Finally, when we created 10 000 random DEG subsets by sampling 75% of the genes from the DEG set, all subsets were significantly genetically associated (least significant P < 3.1 × 10 −11 , permutation-based FDR < 1 × 10
), demonstrating that the genetic association is not the result of a few highly associated genes.
Causal relevance of differentially connected genes
The gene set of differentially connected genes was significantly enriched in the GWAS (P < 1.5 × 10 −15 , permutation-based FDR < 1 × 10
−6
). Furthermore, using the second best SNP did not lead to a significant change in the association of the gene set (P < 6 × 10
, permutation-based FDR < 1 × 10 −6 ); the gene set remained highly significant in the LD-pruned GWAS results (P < 5.1 × 10 −13 , permutation-based FDR < 1 × 10 −6 ) and when we created 10 000 random gene subsets by sampling 75% of the genes from the gene set, all subsets were significantly genetically associated (least significant P < 9.2 × 10 −7 , permutation-based FDR < 1 × 10 −6 ).
We created three further gene sets: (1) genes differentially expressed without being differentially connected, (2) genes differentially connected without being differentially expressed and (3) genes both differentially connected and expressed. All of these additional gene sets were significantly enriched in the GWAS (P < 6 × 10 , respectively; permutation-based FDR < 1 × 10 −6 for all gene sets).
Therapeutic relevance of transcriptomic changes
The DEG lists from a number of microarray studies on brain tissue from epilepsy surgery have statistically significant overlaps with targets of current AEDs (Table 3 ), but the most significant overlap by far was for our microarray study (FDR = 2.75 × 10 −6 ).
The differentially connected gene set and the subset of genes that were differentially connected without being differentially expressed and the subset of genes both differentially connected and expressed did not exhibit significant overlaps with AED targets.
Pathways and networks
Pathway-enrichment analysis of the 1009 DEGs with valid gene symbols revealed 91 significantly enriched pathways (FDR < 0.05). The top 10 significantly enriched pathways are listed in Table 4 .
Pathway-enrichment analysis of the 890 differentially connected genes revealed 75 significantly enriched pathways (FDR < 0.05). The top 10 significantly enriched pathways are listed in Table 4 . We further confirmed that these pathways are differentially connected (FDR < 0.05) using the GSCA package.
Thus, we identified 118 unique differentially regulated (differentially expressed or differentially connected) Reactome pathways. Out of these, 48 pathways (41%) were both differentially expressed and differentially connected, 43 pathways (36%) were only differentially expressed and 27 pathways (23%) were solely differentially connected.
Enrichment Map analysis revealed a highly interconnected central network of pathways (Fig. 2) . In this central network, each pathway is directly connected to, on average, 13 other pathways. In order to identify the most central 'hub' pathways, 'closeness centrality' network analysis was performed; the results are illustrated in Figure 3 and the complete ranked list can be found in the Supplementary Table S4 . The most central pathways were: (FDR < 9.7 × 10 −4 ) and PKA/CREB signalling (FDR < 9.5 × 10 −3 ). Statistically significant (FDR < 0.05) enrichment of these four pathways was confirmed in a focal epilepsy GWAS meta-analysis (4). The remaining two pathways (GPCR signalling and adaptive immune system) were not significantly associated with the GWAS.
Discussion
We have identified differentially expressed and differentially connected genes and pathway in the human epileptic focus, shown that the pathways form a highly interconnected central network, identified the most central hub pathways in the network and demonstrated objectively that our findings are likely to be causally relevant.
Differentially expressed and differentially connected pathways
Diseases can result from a deregulation of genes that does not significantly affect each gene's average expression level. For these reasons, it is being increasingly appreciated that focusing solely on differential expression and overlooking other types of differential regulation, such as differential connectivity (also known as differential co-expression or differential correlation), can be critically limiting (11) . We have revealed for the first time that there is widespread differential connectivity in the pharmacoresistant epileptic hippocampus. Differential connectivity analysis algorithms can be divided into two distinct types: (1) targeted approaches study gene modules that are defined a priori, whereas (2) untargeted approaches aim at grouping genes into modules on the basis of their differential correlation status. In order to ensure that our results are reliable, we utilized both an untargeted (DICER) and a targeted (GSCA) approach.
Differential expression and differential connectivity pathway analyses confirm and complement each other. Of the 118 unique differentially regulated (differentially expressed or differentially connected) pathways we identified, 41% were both differentially expressed and differentially connected, but 36% were only differentially expressed, and 23% were solely differentially connected. This point is further highlighted by looking at the ten most differentially expressed and the ten most differentially connected pathways (Table 4 ). Common to both are pathways related to the neuronal system, transmission across chemical synapses and SLC-mediated transmembrane transport of small molecules. However, prominent amongst the most differentially expressed pathways, but not amongst the most differentially connected pathways, are pathways related to ligand binding to GPCR, especially class A1 rhodopsin-like receptors such as chemokine receptor 1 (CCR1) and the resultant downstream signalling events. In contrast, prominent amongst the most differentially connected pathways, but not amongst the most differentially expressed pathways, are pathways related to axon guidance, especially via semaphorins. These observations demonstrate that considering only one form of differential regulation (that is, only differential expression or only differential connectivity) may lead to important biological processes being overlooked.
Targeting the most important pathways: complexity to coherence to centrality
The differentially expressed and differentially connected Reactome pathways identified in our microarray analysis present a complex picture as they appear to represent disparate and disconnected processes, for example 'axon guidance', 'transmembrane transport of small molecules' and 'class A1 rhodopsin-like receptors'. If these pathways work together to bring about a specific phenotype, they must form a coherent whole. Indeed, we have shown that these differentially expressed and differentially connected pathways form a highly interconnected central network (Fig. 2) . In this central network, each pathway is directly connected, on average, to 13 other pathways. The seemingly unrelated pathways, therefore, do form a coherent whole, and it can be expected that changes in one pathway in this network will have a cascading effect on the rest of the network. The underlying assumption is that the dysfunction of a pathway will spread to overlapping pathways with which it shares constituent genes.
The most important pathways in this network are likely to be the 'hub pathways' identified using closeness centrality network analysis. Closeness centrality is a measure of how fast information spreads from a given node to other reachable nodes in the network (12) . Hence, dysfunction of the most central pathways will spread most readily to other pathways in the network and is likely to have the most significant impact upon the network. Centrality measures have successfully been applied in other biological domains (13) . For example, Jeong and colleagues studied the protein-protein interaction network of yeast in order to predict lethal mutations (8) . They showed that the network is tolerant to random errors, whereas errors related to the most central proteins cause lethality.
The most central pathways we identified include signalling by GPCRs, in particular opioid receptors; calcium-dependent events; DAG and IP 3 signalling; and PKA-mediated phosphorylation of CREB.
Causal and therapeutic relevance of our findings A limitation inherent in transcriptomic studies is that the gene expression changes identified can be a consequence, rather than a cause, of the disease. Gene sets derived from transcriptomic studies are deemed causally relevant if the gene sets are genetically associated in independent genome-wide association studies of the disease. This strategy has been applied in a number of published studies (14) (15) (16) (17) . For the first time, we have provided objective evidence validating this technique. It has been shown recently that Mandelian genes known to cause a disease can contribute to sporadic forms of the disease (18) . In the current work, we have shown that proven causal epilepsy genes, which cause familial Mendelian epilepsy syndromes, are associated in a focal sporadic epilepsy GWAS analysis.
The DEG sets from a number of microarray studies on brain tissue from epilepsy surgery were significantly enriched in the focal epilepsy GWAS, but the most significant enrichment by far was for our microarray study (Table 3) . Also, our set of differentially connected genes was highly associated in the GWAS analyses. Importantly, random subsets of our dysregulated gene sets were also genetically associated indicating that the associations could not be attributed to a small number of the genes, but rather most of the genes in the gene sets likely contribute to the genetic associations.
The discovery of new therapeutic targets is one of the main motivations behind conducting microarray studies in epilepsy. The underlying assumption is that the dysregulated gene set identified by the microarray analysis represents a narrowed search space enriched with drug targets in which it is easier to discover potential new targets. If it can be shown that this search space is enriched with already proven drug targets, then this lends credence to the underlying assumption. We demonstrated that the DEG lists from a number of microarray studies on brain tissue from epilepsy surgery have statistically significant overlaps with targets of current AEDs, but the most significant overlap by far was for our microarray study. This shows that our list of DEGs is likely to be a highly valuable resource for future drug discovery.
The above observations illustrate that the dysregulated genes and pathways identified are likely to be causally and therapeutically relevant. In addition, our results are more causally and therapeutically relevant than other published microarray studies. This is likely to be due to our optimal data-processing strategies, for example applying ComBat and ISVA, which ensure that more false positives are filtered out from our results and our results are more enriched with true positives.
The above observations also raise further interesting questions: if DEGs within epileptic foci of patients with pharmacoresistant epilepsy are enriched with targets of currently available AEDs, why are these drugs ineffective in controlling seizures in such patients? Also, are new targets chosen from the DEG set likely to be useful in tackling drug resistance, when current targets present within the DEG set have proven inadequate? To answer the first of these two questions, we must consider the mechanism of pharmacoresistance in epilepsy. A number of hypotheses explaining drug resistance in epilepsy have been put forward. The most intuitive of these is the 'intrinsic severity hypothesis' (19) , which states that pharmacoresistance is a manifestation of higher disease severity secondary to increased dysfunction of the neurobiological processes underlying epilepsy. As our analysis has demonstrated, underlying epilepsy is a dysregulated network consisting of many diverse pathways and processes. A possible explanation of AED failure is that currently employed drug regimens, acting upon a small number of these disease pathways, have an inadequate rectifying effect upon the dysregulation of the whole network. Hence, the effort to develop more efficacious therapies in epilepsy is likely to benefit from strategies that take cognizance of the complexity, coherence and centrality of the genomic dysregulation underlying epilepsy. One such strategy would be to exploit transcriptomic data sets, such as the one presented here, to find rational combinations of AEDs that target complimentary critical disease pathways. Such approaches are already being employed in the realms of cancer chemotherapy with tools such as DrugComboRanker (20) . In order to execute this strategy to its fullest potential, the full transcriptomic profiles of current AEDs will need to be elucidated. Another strategy for developing more efficacious antiepileptic therapies is to target the pathways that are most critical and central in the disease network underlying epilepsy. Drugs targeting the most central causal pathways are likely to exert the greatest influence upon the disease network. Our analysis shows that none of the currently available AEDs target the most central causal pathways underlying epilepsy (discussed in the next section).
Although there was no significant overlap between the differentially connected genes and AED targets, the putative causal relevance of the differentially connected genes, as demonstrated by their significant GWAS enrichment, suggests that they also need to be given careful consideration in the search for novel drug targets. Compared with the great diversity of pathways dysregulated within the epileptic focus, current AEDs target genes belonging to relatively few functional classes, such as voltage-gated ion channels and neurotransmitter receptors (21) . While many of these functional classes (and, hence, AED targets) were found within the DEGs, the functional classes within the differentially connected gene set were quite different, as described earlier and, hence, its overlap with AED targets was lower.
It is noteworthy that the DEG list from the microarray analysis by Venugopal et al. (22) has a statistically significant overlap with our study but no significant overlap with the AED targets gene set. Please recall that it is possible for each of two small gene sets A and B to have a statistically significant overlap with a large reference gene set C, even if A and B do not have a significant overlap with each other. The study by Venugopal et al. has less than half the number of samples included in our analysis and, hence, possesses lower power to identify genes dysregulated in the epileptic focus. Consequently, the Venugopal et al. DEG list is less than half the size of the DEG list identified in our analysis. Hence, Venugopal et al. are able to identify only a subset of the truly dysregulated genes. Also, the AED targets gene set represents only a small subset of the truly dysregulated genes. We found that both the AED targets gene set and the Venugopal et al. DEG set have significant overlaps with our DEG set, without significantly overlapping with each other. The less significant overlaps with the AED targets gene set observed for the Lee 
Central causal pathways
We identified GPCR signalling as most central in the network of dysregulated pathways within the human epileptic focus (see above). GPCRs comprise the largest and most diverse gene super-family in humans (23) and are divided into numerous families and subfamilies. In response to activation, a GPCR changes its structural conformation and transduces this into intracellular signals. The many different signalling pathways that can be activated by GPCRs include (24) the cAMP/PKA pathway, the calcium/protein kinase C (PKC) pathway, the IP3/DAG/ phospholipase C pathway, the β-arrestin pathway, the protein tyrosine kinase pathway, the ERK/MAPK pathway, the PI3K/ AKT pathway, the Rho pathway and G-protein-gated ion channels including calcium channels and G-protein-gated inwardly rectifying potassium channels. From amongst the numerous GPCR subfamilies and intracellular signalling pathways, our centrality and genetic-association analysis highlights opioid receptor, DAG/IP 3 , calcium-dependent events (which are essential for IP 3 signalling), and PKA/CREB pathways as being central and causal.
Published studies, including functional work in animal models, have shown that the aforementioned pathways play a role in epilepsy and seizures. For example, knockout mice lacking an endogenous opioid peptide are epileptic (25) . There are changes in the expression of endogenous opioids and in opioid receptor binding in genetic animal models of epilepsy before the occurrence of seizures (26, 27 ). An extensive literature, for example (25, (28) (29) (30) (31) (32) (33) (34) (35) , describes how compounds acting on opioid receptors influence seizure susceptibility. Endogenous and exogenous opioids also exert antiepileptogenic and neuroprotective effects in animal epilepsy models (25, 36) . Transgenic mice which express ∼10% of wild-type CREB levels have a ∼50% reduction in spontaneous seizures following pilocarpine-induced status epilepticus and require more stimulation to electrically kindle (37) . Epileptiform activity in cultured neurons is inhibited by IP 3 -receptor blocker Xestospongin C (38) . However, paradoxically, IP 3 -receptor knockout mice exhibit epilepsy (39) . The DAG kinase (DGK) family of enzymes fulfils a critical role in DAG signalling by terminating the 'DAG signal' and regulating the basal state of DAG. Leach and colleagues reported a female patient with a de novo balanced translocation that caused deletion of the DGKδ2 gene who exhibited seizures (40) . Also, mutant mice lacking DGKδ2 were shown to experience seizures (40) .
We acknowledge that alternative methods of network construction are available, for example by including protein-protein interaction data (41) . We have opted for a simple and intuitive approach not reliant on strong assumptions. Also, there are likely to be other causal pathways in addition to the ones we have identified. However, according to our results, the pathways identified occupy key central positions in the causal network of dyregulated pathways.
In summary, dysregulation of opioid GPCR signalling, especially through the PKA/CREB and DAG/IP 3 pathways, is one of the most central potentially causal processes underlying epilepsy. A number of published functional studies provide evidence of a role for these pathways in producing epilepsy and seizures. The novel contribution of our work is to highlight the central causal role of these pathways in human focal epilepsy. It has been suggested that GPCRs are the largest set of therapeutic drug targets for known medicinal agents (42, 43) , being targeted by ∼50% of all modern medicinal drugs (44) . However, none of the currently available AEDs specifically target GPCRs in general and opioid receptors in particular. Based on our findings, these signalling pathways should be the focus of concerted research efforts in order to exploit them as potential AED targets, possibly through drug repositioning (45) .
Materials and Methods
Sample collection
The study was approved by the Northwest 2 Research Ethics Committee. Informed consent was obtained from tissue donors. Samples used in the study originated from three UK sites: the Walton Centre for Neurology and Neurosurgery in Liverpool, the Salford Royal Hospital in Salford and the Southern General Hospital in Glasgow. We recruited patients with pharmacoresistant mesial temporal lobe epilepsy for whom a therapeutic temporal lobectomy was being undertaken. After surgery, the hippocampus was divided into two portions: (1) one portion was preserved for RNA isolation and (2) the other portion underwent histological analysis by an experienced neuropathologist. Patient inclusion and exclusion criteria and sample handling procedures are detailed in the Supplementary Material.
Frozen post-mortem histologically normal hippocampal samples from donors with no known brain diseases were obtained from the MRC Edinburgh Brain Bank (Edinburgh, UK) and the Queen Square Brain Bank (London, UK).
RNA isolation
Brain samples were disrupted and homogenized in an appropriate volume of QIAzol lysis reagent (Qiagen, Crawley, United Kingdom) by using a TissueRuptor handheld rotor-stator homogenizer (Qiagen). Total RNA was extracted from the homogenates using the RNeasy Lipid Tissue Mini Kit (Qiagen), according to the manufacturer's instructions. RNA quality was examined by capillary electrophoresis on an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA), and Agilent 2100 Expert software was used to calculate the RNA integrity number (RIN) of each sample. Purity of the RNA sample was assessed using a NanoDrop1000 Spectrophotometer. Capillary electrophoresis traces were also examined. Samples with RIN scores (RIN) below 6, obvious RNA degradation, significant 18S or 28S ribosomal RNA degradation, ratio of absorbance at 260 and 280 nm <1.95, or with noticeable DNA or background contaminants did not pass QC and were withheld from microarray analysis.
Microarray processing and quality control
The microarrays were processed at the Centre for Genomics Research in the University of Liverpool (http://www.liv.ac.uk/ genomic-research/, last accessed on 1 March 2015). A concentration of 50 ng of total RNA was amplified and labelled using the Agilent Low Input Quick Amp One-Colour Labeling Kit, and labelled RNA was hybridized to Agilent SurePrint G3 Custom 8 × 60 K Microarrays designed to contain probes for all known genes. Standard Agilent protocols were followed. Stringent QC criteria were applied, which are detailed in the Supplementary Material. One array failed on five of the QC criteria and, hence, was excluded. Intensity data were extracted from the remaining arrays using the Feature Extraction Software, in line with the manufacturer's recommendations.
We employed an unbiased approach for the detection of outlier samples: samples with average inter-array correlation ≤2 standard deviations below the mean were removed. This approach has been used successfully in published studies (46) (47) (48) .
Data normalization, adjustment and filtering
Features that were population outliers, saturated or non-uniform were flagged as 'Compromised' and filtered out. Non-expressed probes were filtered out: a probe was deemed expressed only if it was flagged 'Detected' in at least 25% of control or case samples. Quantile normalization was applied. Batch effect was corrected using the ComBat (49) algorithm implemented in the SVA Bioconductor package. Eight arrays (four cases and four controls) were processed per slide; hence, each batch comprised the eight samples processed together on a slide. To adjust for known and unknown confounders, ISVA (50) was applied; RIN, age and sex were explicitly included in the ISVA adjustment. Where multiple probes mapped to the same gene and mRNA variant, the probe with the highest variance was retained, as the most variant probe is likely to be most informative.
Assessing the influence of confounders
To determine whether there was residual confounding after data adjustment, we used the phenoTest Bioconductor package to test for association between probes and confounders (batch, RIN, age and sex).
Differential expression analysis
Differential expression analysis of the adjusted data set was performed using the limma package (51) . A probe was considered differentially expressed if FDR was <0.05 and FC was ≥1.5.
External validation of differential expression
As robust validation of our differential expression results, we determined whether there was significant overlap and rank-order similarity between our results and the results from three previous microarray studies on hippocampal tissue from epilepsy surgery (22, 52, 53) . For comparison, we determined whether our results show a significant overlap and a significant rank-order similarity with a previously published microarray study on hippocampal tissue from Alzheimer's disease sufferers (54) .
Statistical significance of overlap was calculated using the hypergeometric equation, and statistical significance of rank-order similarity was calculated using the OrderedList Bioconductor package (55) .
Differential connectivity
For performing differential connectivity analysis, we used the algorithm DICER (9) .
Including all microarray probes in the analysis was not computationally feasible: the time and memory requirements were both prohibitive. Hence, the probes were sequentially filtered as follows: (1) only probes mapping to genes with valid current Entrez numbers and HUGO Gene Nomenclature Committee gene symbols were retained, (2) where multiple probes mapped to the same gene, the most variant probe only was retained and (3) the 10 000 probes with the highest variance were retained. Hence, after filtering, 10 000 probes with high variance remained, each mapping to a unique gene.
The genes in differentially connected clusters from DICER were used to perform pathway-enrichment analysis. For the enriched pathways, differential connectivity was further confirmed using the Gene Set Co-Expression Analysis (56) protocol.
Assessing the potential causal relevance of transcriptomic changes
We wished to determine whether genetic association in a sporadic GWAS analysis could be used to discriminate causally relevant from irrelevant gene sets. We created a set of proven causal epilepsy genes by extracting from the Online Mendelian Inheritance in Man database (www.omim.org) genes which cause familial Mendelian disorders in which epilepsy/seizures are a primary feature. We determined whether this causal gene set is genetically associated with focal epilepsy. We used the results from a previously published focal epilepsy GWAS (10) that included 3445 individuals with focal epilepsy. Complete genome-wide results for the GWAS were downloaded from the authors' websites. The GSA-SNP program (57) has been used successfully for showing genetic associations of gene sets (58) . To increase the computational efficiency of calculating permutation-based FDRs, the z-score method of the GSA-SNP program was implements in R (version 3.0.1). For SNP-to-gene mapping, we used a mapping distance of 20 kb. Each SNP was mapped to one gene only. Where multiple SNPs mapped to the same gene, the best (most significantly associated) SNP was used. We determined whether the causal gene set is significantly enriched in the results of the GWAS analysis. We calculated a permutation-based FDR by generating 1 000 000 random gene sets of the same size as the causal gene set and determining whether any of the random gene sets were as enriched in the GWAS analysis as the causal gene set. If several genes in the gene set are physically close together, LD could cause multiple genes in the set being counted as significant from a single association signal, thereby falsely inflating the apparent enrichment of the set. To check for this possibility, we LD-pruned the results of the GWAS by Kasperaviciute and colleagues. Wellcome Trust Case Control Consortium (WTCCC) 1958 British Birth Cohort data set (EGAD00000000022) was used as the reference genotype data set for calculating LD. LD pruning was performed using the clump function in plink 1.9 (flags: -clump-p1 1 -clump-p2 0.01 -clump-r2 0.50 -clumpkb 1000). Starting with the most significant SNP, other SNPs that were <1000 kb away and had r 2 ≥ 0.5 with it were pruned out. GWAS enrichment of the causal gene set was re-calculated using the LD-pruned results. We determined whether our DEG set is significantly enriched in the results of the GWAS analysis. For comparison, we did the same analysis for all previously published microarray studies on brain tissue from epilepsy surgery.
We performed a number of additional analyses to demonstrate that the enrichment of our DEG set in the GWAS results was unlikely to be spurious:
1. We calculated a permutation-based FDR by generating 10 00 000 random gene sets of the same size as our DEG set and determining whether any of the random gene sets were as enriched in the GWAS analyses as our DEG set. 2. In order to determine whether our DEG-set association might be artificially inflated owing to random SNPs being highly associated by chance in the GWAS, we repeated the analysis using the first-and second-best SNP mapping to each gene. 3. GWAS enrichment of the DEG set was re-calculated using LD-pruned GWAS results.
Human Molecular Genetics, 2015, Vol. 24, No. 15 | 4313 4. We wished to determine whether GWAS enrichment of the DEG set is due to a few highly associated genes. We created random subsets of the DEG set by sampling 75% of the genes 10 000 times. We determined the enrichment of the random DEG subsets in the GWAS results.
We also used the above-mentioned methods to show the causal relevance of differentially connected genes.
A meta-analysis of focal epilepsy GWAS studies has recently been published (59) . It was not possible to accurately LD-prune the GWAS met-analysis as it contained significantly more SNPs than the available reference genotype data set. Hence, the primary GWAS by Kasperaviciute and colleagues was used for the above-mentioned analyses. However, the genetic association of the most central pathways was also verified using the GWAS meta-analysis results (see below). It should be noted that the GWAS by Kasperaviciute and colleagues was one of the studies included in the meta-analysis, contributing ∼65% of the individuals to it.
Assessing the potential therapeutic relevance of transcriptomic changes
We created a comprehensive list of the targets of all current antiepileptic drugs (AEDs) in an unsupervised and unbiased manner by searching three publically available databases of drug targets: Stitch, SuperTarget and DrugBank. We then determined whether our DEG set was enriched with AED targets by calculating the statistical significance of the overlap between AED targets and our DEG list. For comparison, we did the same analysis for all previously published microarray studies on brain tissue from epilepsy surgery.
Pathway-enrichment analysis
Pathway-enrichment analysis was performed using the Reactome database on the Gene Set Enrichment Analysis website (http://www.broadinstitute.org/gsea/, last accessed on 1 March 2015).
Network of pathways and central pathways
Enrichment Map (60) tool was used to determine the connections between enriched pathways. We employed an overlap coefficient cut-off of 0.25-two pathways were deemed connected only if the ratio of the size of the intersection over the size of the smallest pathway was 0.25 or more. The Network Analysis tool was used to calculate network parameters, including 'closeness centrality' of nodes.
It should be noted that in the Reactome database, pathways are assembled into a top hierarchy of biological processes. The top hierarchy of biological processes represent very broad categories, such as 'Developmental Biology' and 'Neuronal System'. These biological processes were excluded from the list of pathways before network creation, as these broad terms are likely to occupy central positions in the network, overshadowing more specific terms and hindering identification of specific key pathways. Filtering out of the broadest functional categories has been employed by widely used annotation platforms, such as the GO Fat database in the DAVID suite of bioinformatics resources (61) .
Next, we determined whether any of the most central pathways are significantly (FDR < 0.05) enriched within the results of the focal epilepsy GWAS (10) . The enrichment was confirmed using the LD-pruned GWAS results. We further verified the significant results by determining enrichment in a published meta-analysis (59) of focal epilepsy GWAS studies. It should be noted that the GWAS by Kasperaviciute and colleagues was one of the studies included in the meta-analysis.
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